bDMARD (n = 14) | csDMARD-only (n = 18) | p-value* | |
---|---|---|---|
Acute phase symptoms | |||
Fever | 13 (92.9) | 18 (100.0) | 0.437 |
Rash | 7 (50.0) | 9 (50.0) | 1.000 |
Morning Stiffness | 10 (71.4) | 13 (72.2) | 1.000 |
Fatigue | 7 (50.0) | 15 (83.3) | 0.062 |
Itching | 5 (35.7) | 8 (44.4) | 0.618 |
Paraesthesia | 4 (28.6) | 9 (50.0) | 0.221 |
Lower limb edema | 6 (42.9) | 11 (61.1) | 0.305 |
Myalgia | 7 (50.0) | 14 (77.8) | 0.142 |
Arthritis | 12 (85.7) | 16 (88.9) | 1.000 |
Headache | 9 (64.3) | 16 (88.9) | 0.195 |
Gastrointestinal symptoms | 3 (21.4) | 06 (33.3) | 0.694 |
Respiratory symptoms | 3 (21.4) | 04 (22.2) | 1.000 |
Worsening of articular symptoms after the acute phase | |||
None | 0 (0.0) | 0 (0.0) | 0.283 |
Mild | 1 (7.1) | 0 (0.0) | |
Moderate | 2 (14.3) | 3 (16.7) | |
Severe | 8 (57.1) | 7 (38.9) | |
Very severe | 3 (21.4) | 8 (44.4) | |
Persistence of articular symptoms for > 3 months | 2 (14.2) | 10 (55.6) | 0.017 |
Treatment switch | 3 (21.4) | 11 (61.1) | 0.025 |
Change in corticosteroid dose | 4 (28.6) | 8 (44.4) | 0.357 |